Macular Cystoid Edema Induced by Nab-Paclitaxel

Detalhes bibliográficos
Autor(a) principal: Alves Pereira, Sara
Data de Publicação: 2022
Outros Autores: Vale, Carolina, Moreira, Jorge, Sampaio, Filipa
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/13421
Resumo: A 61-year old male was referred to the Ophthalmology department because of decreased bilateral visual acuity. The patient had metastatic pancreatic adenocarcinoma and was being treated with gemcitabine+nab-paclitaxel. On examination, the patient presented best corrected visual acuities of 4/20 and 2/20 in the right and left eye, respectively. The optical coherence tomography revealed bilateral severe macular edema. Macular edema was considered secondary to nab-paclitaxel and the drug was discontinued. Three months after drug discontinuation, the patient presented best corrected visual acuities of 20/20 and 16/20 in the right and left eye, respectively, and normal fundoscopy. Macular edema is a very rare side effect of taxanes, and the etiopathology is still unknown. Edema is usually reversible upon discontinuation of the offending agent. Clinicians should be aware of this adverse effect of taxanes, and a high index of clinical suspicion is essential for diagnosis.
id RCAP_47c8082ea89489bfd32df3e69b1d075c
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/13421
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Macular Cystoid Edema Induced by Nab-PaclitaxelEdema Macular Cistóide Secundário ao Nab-PaclitaxelAlbumins/adverse effectsAlbumin-Bound Paclitaxel/adverse effectsMacular Edema/chemically inducedPaclitaxel/adverse effectsPancreatic Neoplasms/drug therapyAlbuminas/efeitos adversosEdema Macular/induzido quimicamenteNeoplasias Pancreáticas/tratamento farmacológicoPaclitaxel/efeitos adversosPaclitaxel Ligado a Albumina/efeitos adversosA 61-year old male was referred to the Ophthalmology department because of decreased bilateral visual acuity. The patient had metastatic pancreatic adenocarcinoma and was being treated with gemcitabine+nab-paclitaxel. On examination, the patient presented best corrected visual acuities of 4/20 and 2/20 in the right and left eye, respectively. The optical coherence tomography revealed bilateral severe macular edema. Macular edema was considered secondary to nab-paclitaxel and the drug was discontinued. Three months after drug discontinuation, the patient presented best corrected visual acuities of 20/20 and 16/20 in the right and left eye, respectively, and normal fundoscopy. Macular edema is a very rare side effect of taxanes, and the etiopathology is still unknown. Edema is usually reversible upon discontinuation of the offending agent. Clinicians should be aware of this adverse effect of taxanes, and a high index of clinical suspicion is essential for diagnosis.Doente do sexo masculino, de 61 anos de idade, foi encaminhado para Oftalmologia por queixas de diminuição da acuidade visual bilateral. Tratava-se de um doente com um adenocarcinoma pancreático metastizado, sob tratamento com gemcitabina+nab-paclitaxel. Ao exame oftalmológico, o doente apresentava melhores acuidades visuais corrigidas de 4/20 e 2/20 do olho direito e esquerdo, respetivamente. A tomografia de coerência ótica revelou a presença de edema macular bilateral grave. O edema macular foi considerado secundário ao uso de nab-paclitaxel, pelo que o fármaco foi suspenso. Três meses após a suspensão do fármaco, o paciente apresentava acuidades visuais de 20/20 e 16/20 do olho direito e esquerdo, respetivamente, e uma fundoscopia normal. O edema macular é um efeito adverso muito raro dos taxanos e a sua etiopatologia ainda não se encontra totalmente esclarecida. O edema é habitualmente reversível após a suspensão do agente causador. Um elevado índice de suspeição é essencial para o diagnóstico desta condição.Ordem dos Médicos2022-04-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/13421oai:ojs.www.actamedicaportuguesa.com:article/13421Acta Médica Portuguesa; Vol. 35 No. 4 (2022): April; 294-297Acta Médica Portuguesa; Vol. 35 N.º 4 (2022): Abril; 294-2971646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/13421https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/13421/6399Direitos de Autor (c) 2021 Acta Médica Portuguesainfo:eu-repo/semantics/openAccessAlves Pereira, SaraVale, CarolinaMoreira, JorgeSampaio, Filipa2022-12-20T11:06:52Zoai:ojs.www.actamedicaportuguesa.com:article/13421Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:20:20.912055Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Macular Cystoid Edema Induced by Nab-Paclitaxel
Edema Macular Cistóide Secundário ao Nab-Paclitaxel
title Macular Cystoid Edema Induced by Nab-Paclitaxel
spellingShingle Macular Cystoid Edema Induced by Nab-Paclitaxel
Alves Pereira, Sara
Albumins/adverse effects
Albumin-Bound Paclitaxel/adverse effects
Macular Edema/chemically induced
Paclitaxel/adverse effects
Pancreatic Neoplasms/drug therapy
Albuminas/efeitos adversos
Edema Macular/induzido quimicamente
Neoplasias Pancreáticas/tratamento farmacológico
Paclitaxel/efeitos adversos
Paclitaxel Ligado a Albumina/efeitos adversos
title_short Macular Cystoid Edema Induced by Nab-Paclitaxel
title_full Macular Cystoid Edema Induced by Nab-Paclitaxel
title_fullStr Macular Cystoid Edema Induced by Nab-Paclitaxel
title_full_unstemmed Macular Cystoid Edema Induced by Nab-Paclitaxel
title_sort Macular Cystoid Edema Induced by Nab-Paclitaxel
author Alves Pereira, Sara
author_facet Alves Pereira, Sara
Vale, Carolina
Moreira, Jorge
Sampaio, Filipa
author_role author
author2 Vale, Carolina
Moreira, Jorge
Sampaio, Filipa
author2_role author
author
author
dc.contributor.author.fl_str_mv Alves Pereira, Sara
Vale, Carolina
Moreira, Jorge
Sampaio, Filipa
dc.subject.por.fl_str_mv Albumins/adverse effects
Albumin-Bound Paclitaxel/adverse effects
Macular Edema/chemically induced
Paclitaxel/adverse effects
Pancreatic Neoplasms/drug therapy
Albuminas/efeitos adversos
Edema Macular/induzido quimicamente
Neoplasias Pancreáticas/tratamento farmacológico
Paclitaxel/efeitos adversos
Paclitaxel Ligado a Albumina/efeitos adversos
topic Albumins/adverse effects
Albumin-Bound Paclitaxel/adverse effects
Macular Edema/chemically induced
Paclitaxel/adverse effects
Pancreatic Neoplasms/drug therapy
Albuminas/efeitos adversos
Edema Macular/induzido quimicamente
Neoplasias Pancreáticas/tratamento farmacológico
Paclitaxel/efeitos adversos
Paclitaxel Ligado a Albumina/efeitos adversos
description A 61-year old male was referred to the Ophthalmology department because of decreased bilateral visual acuity. The patient had metastatic pancreatic adenocarcinoma and was being treated with gemcitabine+nab-paclitaxel. On examination, the patient presented best corrected visual acuities of 4/20 and 2/20 in the right and left eye, respectively. The optical coherence tomography revealed bilateral severe macular edema. Macular edema was considered secondary to nab-paclitaxel and the drug was discontinued. Three months after drug discontinuation, the patient presented best corrected visual acuities of 20/20 and 16/20 in the right and left eye, respectively, and normal fundoscopy. Macular edema is a very rare side effect of taxanes, and the etiopathology is still unknown. Edema is usually reversible upon discontinuation of the offending agent. Clinicians should be aware of this adverse effect of taxanes, and a high index of clinical suspicion is essential for diagnosis.
publishDate 2022
dc.date.none.fl_str_mv 2022-04-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/13421
oai:ojs.www.actamedicaportuguesa.com:article/13421
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/13421
identifier_str_mv oai:ojs.www.actamedicaportuguesa.com:article/13421
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/13421
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/13421/6399
dc.rights.driver.fl_str_mv Direitos de Autor (c) 2021 Acta Médica Portuguesa
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Direitos de Autor (c) 2021 Acta Médica Portuguesa
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 35 No. 4 (2022): April; 294-297
Acta Médica Portuguesa; Vol. 35 N.º 4 (2022): Abril; 294-297
1646-0758
0870-399X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130651867217920

Registros relacionados